ADMA Biologics Valuation Multiples

ADMA Biologics Overview

About ADMA Biologics

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.

Founded

2004

HQ

Employees

647

Website

admabiologics.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $544M

EBITDA: $266M

EV

$3B

Valuation Multiples

Multiples.vc

Start free trial

ADMA Biologics Financials

ADMA Biologics reported last 12-month revenue of $544M and EBITDA of $266M.

In the same LTM period, ADMA Biologics generated $319M in gross profit, $266M in EBITDA, and $170M in net income.

ADMA Biologics P&L

In the most recent fiscal year, ADMA Biologics reported revenue of $510M and EBITDA of $231M.

ADMA Biologics expects next 12-month revenue of XXX and NTM EBITDA of XXX

ADMA Biologics Stock Performance

ADMA Biologics has current market cap of $3B, and enterprise value of $3B.

ADMA Biologics' stock price is $11.01.

ADMA Biologics Valuation Multiples

ADMA Biologics trades at 4.7x EV/Revenue multiple, and 9.6x EV/EBITDA.

ADMA Biologics Financial Valuation Multiples

As of April 18, 2026, ADMA Biologics has market cap of $3B and EV of $3B.

Equity research analysts estimate ADMA Biologics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

ADMA Biologics has a P/E ratio of 15.0x.

ADMA Biologics Margins & Growth Rates

ADMA Biologics' revenue in the last 12 month grew by 23%.

ADMA Biologics' revenue per employee in the last FY averaged $0.8M, while opex per employee averaged $0.2M for the same period.

ADMA Biologics' rule of 40 is 78% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

ADMA Biologics' rule of X is 112% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

ADMA Biologics Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

ADMA Biologics M&A Activity

ADMA Biologics acquired XXX companies to date.

Last acquisition by ADMA Biologics was on XXXXXXXX, XXXXX. ADMA Biologics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

ADMA Biologics Investment Activity

ADMA Biologics invested in XXX companies to date.

ADMA Biologics made its latest investment on XXXXXXXX, XXXXX. ADMA Biologics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).